The CReST trial has completed!  Early results were presented at ASCO in 2016 - to view the abstract please click here. 

CReST2 Launch Meeting.

Further details will be available at the CReST2 launch meeting on 28th November 2016 in Birmingham.  Please click here for the meeting invite.  Please click here for the meeting agenda.


The CReST trial was designed to look at the role of endoluminal stenting in the acute management of obstructing colorectal cancer.

This trial was developed by the NCRI Colorectal Cancer Study Group and was funded by Cancer Research UK.

The chief investigators of the CReST trial are:
Professor Richard Gray, Director of BCTU
Mr Jim Hill, Consultant Surgeon, Manchester Royal Infirmary
Dr Clive Kay, Consultant Radiologist, Bradford Royal Infirmary

Primary objectives:

The primary objectives of the CReST RCT were to establish if endoluminal stenting for obstructing colonic cancers can result in:

  • Reduced perioperative morbidity and reduced length of hospital stay.
  • Reduced stoma formation,
  • A measurable improvement in quality of life.


Recruitment to CReST has closed.

If you have questions about the CReST study, please contact the CReST Team at the following Freepost address:

CReST Trials Office,

Birmingham Clinical Trials Unit,
Division of Medical Sciences,
University of Birmingham,
Birmingham B15 2TT
FAX: +44 (0)121 415 8871

Alternatively you can contact the Birmingham Clinical Trials Unit:

Tel: 0121 415 9105